User:Johnfravolda
Appearance
Drug Name | Maker | Disease Category | Purpose | 2006 | 2009 | DrugBank |
---|---|---|---|---|---|---|
ABT-263 | Abbott | Cancer | Lymphoma, etc. | ? | PI | 0 |
ABT-333 | Abbott | Infectious, virus | HCV | ? | PI | 0 |
ABT-143 | Abbott | Cardiovascular | Cholesterol, a statin drug | ? | PIII | 0 |
ABT-335 | Abbott | Cardiovascular | Cholesterol, a statin drug | ? | PIII | 0 |
ABT-510 (Thrombospondin Analogue) | Abbott | Cancer | Head, neck | ? | PII | 0 |
ABT-751 | Abbott | Cancer | non-small cell lung | ? | PI-PII some studies terminated | 0 |
ABT-894 | Abbott | Diabetes | Diabetic Neuropathies | ? | PII | 0 |
ABT-450 | Abbott | Infectious, virus | HCV | ? | PI | 0 |
ABT-874 | Abbott | Autoimmune | Psoriasis | ? | PIII | |
ABT-888 | Abbott | Cancer | Leukimia, Chronic Myeloproliferative Disorders | ? | PI, PII | 0 |
ABT-869 | Abbott | Cancer | Solid tumor, advanced, metastatic | ? | PI PII | 0 |
ABT-102 | Abbott | ? | ? | ? | PI | 0 |
ABT-089 | Abbott | Neurological | ADHD | ? | PII some terminated | 0 |
ABT-126 | Abbott | Neurological | Alzheimer's disease | ? | PI | 0 |
ABT-072 | Abbott | Infectious, virus | HCV | ? | PI | 0 |
Cetrorelix Pamoate | AEterna Zentaris | Prostate | Benign prostatic hyperplasia | ? | PIII | 0 |
CPI-300 | IntelGenx and Cary Pharmaceuticals | Neurological | antidepressant | ? | ? | 0 |
Tigecycline (Tygacil) | Wyeth | Infectious, Antibiotic | MRSA | approved | approved | 00560DB |
Mecasermin (Increlex) | Tercia | Hormone | Growth factor, synthetic IGF-1 | approved | approved | 01277DB |
Dalbavancin (Zeven) | Pfizer | Infectious, Antibiotic | Gram+ (MRSA, MRSE) | Awaiting regulatory decision | PIII active | 0 |
Denosumab (AMG 162) | Amgen | Osteoporosis | Treats osteoporosis | Late-stage trial | PIII active | 0 |
Dimebolin, (Dimebon) | Medivation | Neurological | Alzheimer's disease | ? | PI PII | 0 |
Gardasil | Merck | Infectious, virus | Vaccine prevents hpv/cervical cancer | Late-stage trial | approved | 0 |
Ranibizumab (Lucentis) | Genentech, Novartis | Vision | Treats macular degeneration | Late-stage trial | approved | 01270DB |
Belimumab (Benlysta or LymphoStat-B) | Human Genome Sciences, GlaxoSmithKline | Autoimmune | Treats lupus, rheumatoid arthritis | Mid-stage trial | PII active | 0 |
Maraviroc | Pfizer | Infectious, virus | Treats HIV/AIDS | Late-stage trial | approved | 04835DB |
Aflibercept (AVE005, VEGF-trap) | Regeneron | Cancer | Ovarian cancer | ? | PII PIII | 0 |
Stamulumab (MYO-029) | Wyeth | Muscular dystrophy | Treats muscular dystrophy | Early-stage clinical trial | PII | 0 |
Ciliary Neurotrophic Factor implant (NT-501) | Neurotech USA | Vision | RP, AMD, source of CNTF | ?? | PIII active | 0 |
VEGF structural antagonist implant (NT-503) | Neurotech USA | Vision | wet AMD, source of VEGF antagonist | ?? | ?? | 0 |
Disufenton sodium (NXY-059) | Renovis, AstraZeneca | Neurological | Stroke | Late-stage trial | PIII completed | 0 |
Varenicline (Champix) | Pfizer | Neurological | Smoking addiction | Late-stage trial | approved | 01273DB |
Tarenflurbil (Flurizan) | Myriad Genetics | Neurological | Alzheimer's disease | Late-stage trial | abandoned | 0 |
Gaboxadol | Merck, Lundbeck | Neurological | Sleeplessness | Late-stage trial | abandoned | 0 |
Indiplon | Neurocrine Biosciences, Pfizer | Neurological | Sleeplessness | Late-stage trial | abandoned? | 0 |
Natalizumab(Tysabri, Antegren) | Biogen Idec, Elan | Neurological | Multiple sclerosis | FDA-approved but withdrawn | In use under observation | 00108DB |
Ruboxistaurin (Arxxant) | Eli Lilly | Diabetes | Treat complications | Late-stage trial | PIII active | 0 |
Tesaglitazar (Galida) | AstraZeneca | Diabetes | Lower blood sugar and cholesterol | Late-stage trial | abandoned | 0 |
Vildagliptin (Galvus) | Novartis | Diabetes | Control blood sugar | Late-stage trial | abandoned 2008 | 0 |
Sitagliptin (Januvia, MK-0431) | Merck | Diabetes | Control blood sugar | Late-stage trial | approved | 01261DB |
Darapladib (480848 ) | GlaxoSmithKline | Cardiovascular | Prevent atherosclerosis and heart attack | Late-stage trial | Darapladib | 0 |
Rimonabant (Acomplia) | Sanofi-Synthelabo | Cardiovascular | Combat obesity; reduce risk of heart disease | Awaiting regulatory decision | approved | 06155DB |
AGI-1067 | AtheroGenics | Cardiovascular | Combat artery inflammation | Late-stage trial | abandoned | 0 |
Alfimeprase | Nuvelo | Cardiovascular | Clot-buster | Late-stage trial | abandoned | 0 |
Celacade | Vasogen | Cardiovascular | Treat heart failure | Late-stage trial | Celacade | 0 |
Veliflapon (DG031) | DeCode Genetics | Cardiovascular | Combat artery inflammation | Mid-stage trial | PIII suspended ??deCODE in bankruptcy | 0 |
ETC-216 | Pfizer, Esperion Therapeutics | Cardiovascular | Remove cholesterol from arteries | Mid-stage trial | ?? ETC-216 absent | 0 |
ETC-1002 | Pfizer, Esperion Therapeutics | Cardiovascular | inhibit fatty acid synthesis, promote fatty acid degredation | ?? | Candidates | 0 |
Lipitor-torcetrapib | Pfizer | Cardiovascular | Raise good cholesterol | Late-stage trial | Torcetrapib abandoned | 0 |
CP-690,550 ( JAK-3 inhibitor) | Pfizer | Autoimmune | Rheumatoid Arthritis | ? | PIII | |
LY518674 (PPAR alpha agonist) | Eli Lilly, Ligand Pharmaceuticals | Cardiovascular | Raise good cholesterol, lower triglycerides | Mid-stage trial | ?? | 0 |
Aliskiren (Rasilez) | Novartis | Cardiovascular | Reduce high blood pressure | Late-stage trial | approved | 01258DB |
Sitaxentan (Thelin) | Pfizer, Encysive Pharmaceuticals | Cardiovascular | Treat pulmonary hypertension | Awaiting regulatory decision | 0 approved outside US FDA letter | 0 |
Acapodene | GTx | Cancer | Prostate cancer prevention | Late-stage trial | approved | 00539DB |
Ridaforolimus (AP23573) | Ariad Pharmaceuticals | Cancer | Sarcoma | Mid-stage trial | recruiting PIII | 0 |
Abatacept (Orencia) | Bristol-Myers Squibb | Autoimmune | Rheumatoid arthritis | ? | PIII | 0 |
Dasatinib | Bristol-Myers Squibb | Cancer | Leukemia | Awaiting regulatory decision | approved | 01254DB |
Ipilimumab | Medarex, Bristol-Myers Squibb | Cancer | Melanoma | Late-stage trial | active PIII | 0 |
Panitumumab | Amgen | Cancer | Colon cancer, other tumors | Awaiting regulatory decision | approved | 01269DB |
Vatalanib (PTK-787) | Novartis, Schering | Cancer | Colon cancer | Late-stage trial | active PIII | 0 |
Provenge | Dendreon | Cancer | Prostate cancer | Late-stage trial | active PIII | 0 |
Telcyta (TLK286) | Telik | Cancer | Ovarian cancer | Late-stage trial | active PIII | 0 |
Ticilimumab | Pfizer | Cancer | Melanoma | Mid-stage trial | active PIII | 0 |
Lapatinib | GlaxoSmithKline | Cancer | Breast cancer, bladder cancer | Late-stage trial | approved | 01259DB |
Bavituximab | Perigrine Pharmaceuticals | Cancer | Solid tumer | ? | PI PII | 0 |
Cotara 131I-chTNT-1/B MAb | Perigrine Pharmaceuticals | Cancer | Glioblastoma | ? | PI PII | 0 |
Elesclomol | Synta | Cancer | Melanoma, metastatic | ? | PII some suspended | 0 |
Fostamatinib disodium (R935788) | Rigel | Autoimmune | Rheumatoid arthritis | ? | PII | 0 |
Palladia | Pfizer | Cancer | For Dogs | ? | 0 | |
Arzerra | Genmab, GlaxoSmithKline | Cancer | lymphocytic leukemia | Collab. initiated | PII | 0 |
Apremilast | Celgene | autoimmune | psoriatic arthritis | ? | PII | 0 |
Aldesleukin (Proleukin) | Novartis | Cancer | Metastatic melanoma, metastatic kidney | ? | PI PII | 0 |
Darusentan | Gilead Sciences | Cardiovascular | Hypertension | ? | PIII | 0 |
Stimuvax (BLP25) | Oncothyreon, Merk Serono | Cancer | Carcinoma, Non-Small-Cell Lung; breast cancer | ? | PII PII | 0 |
Ocrelizumab | Genentech | Autoimmune | Rheumatoid arthritis | ? | PII | 0 |
Cixutumumab | ImClone | Cancer | Solid tumors | ? | PII | 0 |
NVA237 | Novartis, Vectura | Pulmonary | chronic obstructive pulmonary disease | ? | PII PIII | 0 |
SEP-225289 | Sepracor | Neurological | Depressive disorder, major | ? | PII | 0 |
Lu AA24530 | Lundbeck | Neurological | Depressive disorder, major | ? | PII | 0 |
PRO-040201 | Tekmira Pharmaceuticals Corporation | Cardiovascular | Hypercholesterolemia | ? | PI | 0 |
TB-402 | ThromboGenics, BioInvent | Cardiovascular | Blood thinner | ? | PII | 0 |
Saxagliptin (Onglyza, BMS-477118) | Bristol-Meyers Squibb | Metabolic | Diabetes, type 2 | ? | PIII | 0 |
This is the start of my user page. I want to contribute to articles pertaining to electricity generation and the politics and economics thereof. It would be great to see more work in this area from various wikipedia contributors.
BPA transmission line uprgrades per 2005[1] | Status | Project Start | Project Completion | Miles | kV | Structure | Capacity increase, MW | Cost per mile | Cost per added watt capacity | Sub-station | Total cost |
---|---|---|---|---|---|---|---|---|---|---|---|
WA | |||||||||||
Franklin to Walla Walla | Pending | 2005 | 2005 | 18.5 | 115 | ? | ? | $302,703 | ? | ? | $5,600,000 |
Grand Coulee to Bell | Completed | ? | 2004 | 84 | 500 | steel latice | 1500 | $1,892,857 | $0.11 | ? | $159,000,000 |
Kangley to Echo Lake | Completed | 2000 | 2003 | 9 | 500 | ? | ? | $9,333,333 | ? | yes | $84,000,000 |
Raymond to Cosmopolis Rebuild | Completed | ? | 2004 | 18 | 115 | s.steel pole | ? | $622,222 | ? | ? | $11,200,000 |
Schultz to Wautona | Construction | ? | 2005? | 63 | 500 | ? | 600 | $2,761,905 | $0.29 | yes | $174,000,000 |
Hopkins Ridge Wind Intercnctn | Pending | 2005 | ? | 115 | ? | ? | 150 | ? | ? | ? | ? |
OR | |||||||||||
Albany to Eugene Rebuild | Completed | 2004 | 18 | 115 | ? | ? | ? | $411,111 | ? | ? | $7,400,000 |
Fort Yamhill Relocation | Pending | 2005 | ? | 115 | ? | ? | ? | ? | ? | ? | ? |
Combine Hills Wind Intercnctn | Pending | 2005 | ? | 5.8 | ? | wood | 63 | ? | ? | ? | ? |
Klondike III Wind Intercntctn | Pending | 2005 | 2006 | 10 | 230 | ? | 300 | ? | ? | ? | ? |
MT | |||||||||||
Libby to Troy Rebuild | Pending | 2005 | 17 | 115 | ? | ? | ? | ? | ? | ? | ? |
ID | |||||||||||
Anderson Ranch to Mountain Home Rebuild | 2004 | 18 | 115 | steel pole | ? | ? | ? | $194,444 | ? | ? | $3,500,000 |
Swan Valley to Goshen Rebuild | 2004 | 2006 | 25 | 161 | ? | wood | ? | $128,000 | ? | ? | $3,200,000 |
HEAD1 | HEAD2 | HEAD3 | HEAD4 | HEAD5 |
---|---|---|---|---|
R1C1 | R1C2 | R1C3 | R1C4 | R1C5 |
R2C1 | R2C2 | R2C3 | R2C4 | R2C5 |